G1 Pharma - GTHX Enterprise Value-to-Sales Ratio

Official company branding of G1 Therapeutics Inc. (GTHX)

G1 Therapeutics, Inc. (GTHX) net income is supported by the licensing of bone marrow protective agents in Europe and Asia. The firm's EV/Sales multiple valuation demonstrates the impact of interest rates on business value, where shows the current level of this metric. Revenues are based on sales of the approved drug, while the development strategy relies on receiving royalties from major pharmaceutical manufacturers.

G1 Therapeutics (GTHX): Company Value to Revenue from 07/04/2022 to 11/20/2026

G1 Therapeutics - analytical breakdowns and key metrics (GTHX)

- cash balance and cash flow data:
Fundamental company valuation:GTHX, G1 Pharma
Manufactured products of g1therapeutics.com

This indicator compares the total enterprise value to sales volume, excluding the impact of leverage to identify the actual market premium per unit of revenue. Analyzing the enterprise value-to-revenue ratio allows for an assessment of the asset's overvaluation, given that the efficient hospital logistics of G1 Therapeutics, Inc. (GTHX) stabilize margins, transforming operational resilience into a foundation for long-term capitalization growth.